150 related articles for article (PubMed ID: 15755993)
1. 2-methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer.
Sutherland TE; Schuliga M; Harris T; Eckhardt BL; Anderson RL; Quan L; Stewart AG
Clin Cancer Res; 2005 Mar; 11(5):1722-32. PubMed ID: 15755993
[TBL] [Abstract][Full Text] [Related]
2. Estrogenic regulation of host immunity against an estrogen receptor-negative human breast cancer.
Curran EM; Judy BM; Duru NA; Wang HQ; Vergara LA; Lubahn DB; Estes DM
Clin Cancer Res; 2006 Oct; 12(19):5641-7. PubMed ID: 17000652
[TBL] [Abstract][Full Text] [Related]
3. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
Morrissey JJ; Raney S
Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
[TBL] [Abstract][Full Text] [Related]
4. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells.
Liu ZJ; Zhu BT
J Steroid Biochem Mol Biol; 2004 Mar; 88(3):265-75. PubMed ID: 15120420
[TBL] [Abstract][Full Text] [Related]
5. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
6. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
Han GZ; Liu ZJ; Shimoi K; Zhu BT
Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evidence for anti-inflammatory properties of 2-methoxyestradiol.
Shand FH; Langenbach SY; Keenan CR; Ma SP; Wheaton BJ; Schuliga MJ; Ziogas J; Stewart AG
J Pharmacol Exp Ther; 2011 Mar; 336(3):962-72. PubMed ID: 21177477
[TBL] [Abstract][Full Text] [Related]
8. Extraction-dependent effects of American ginseng (Panax quinquefolium) on human breast cancer cell proliferation and estrogen receptor activation.
King ML; Adler SR; Murphy LL
Integr Cancer Ther; 2006 Sep; 5(3):236-43. PubMed ID: 16880429
[TBL] [Abstract][Full Text] [Related]
9. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y
Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes.
Harrell JC; Dye WW; Allred DC; Jedlicka P; Spoelstra NS; Sartorius CA; Horwitz KB
Cancer Res; 2006 Sep; 66(18):9308-15. PubMed ID: 16982776
[TBL] [Abstract][Full Text] [Related]
11. Targeted salmon gene array (SalArray): a toxicogenomic tool for gene expression profiling of interactions between estrogen and aryl hydrocarbon receptor signalling pathways.
Mortensen AS; Arukwe A
Chem Res Toxicol; 2007 Mar; 20(3):474-88. PubMed ID: 17291011
[TBL] [Abstract][Full Text] [Related]
12. Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells.
Yu Y; Zhou Q; Hang Y; Bu X; Jia W
Cancer; 2007 Jun; 109(11):2374-82. PubMed ID: 17464948
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions.
Suzuki T; Hayashi S; Miki Y; Nakamura Y; Moriya T; Sugawara A; Ishida T; Ohuchi N; Sasano H
Endocr Relat Cancer; 2006 Mar; 13(1):233-50. PubMed ID: 16601291
[TBL] [Abstract][Full Text] [Related]
15. Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis.
Harrell JC; Dye WW; Harvell DM; Pinto M; Jedlicka P; Sartorius CA; Horwitz KB
Cancer Res; 2007 Nov; 67(21):10582-91. PubMed ID: 17975003
[TBL] [Abstract][Full Text] [Related]
16. 17Beta-estradiol induces down-regulation of Cap43/NDRG1/Drg-1, a putative differentiation-related and metastasis suppressor gene, in human breast cancer cells.
Fotovati A; Fujii T; Yamaguchi M; Kage M; Shirouzu K; Oie S; Basaki Y; Ono M; Yamana H; Kuwano M
Clin Cancer Res; 2006 May; 12(10):3010-8. PubMed ID: 16707596
[TBL] [Abstract][Full Text] [Related]
17. [Angiogenic effect of interleukin-8 in breast cancer and its association with estrogen receptor].
Lin Y; Wang SM; Huang RP
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(20):1419-23. PubMed ID: 16029657
[TBL] [Abstract][Full Text] [Related]
18. Physiologic levels of 2-methoxyestradiol interfere with nongenomic signaling of 17beta-estradiol in human breast cancer cells.
Vijayanathan V; Venkiteswaran S; Nair SK; Verma A; Thomas TJ; Zhu BT; Thomas T
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2038-48. PubMed ID: 16609013
[TBL] [Abstract][Full Text] [Related]
19. 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways.
Vanderlaag K; Su Y; Frankel AE; Grage H; Smith R; Khan S; Safe S
Breast Cancer Res Treat; 2008 May; 109(2):273-83. PubMed ID: 17624585
[TBL] [Abstract][Full Text] [Related]
20. Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells.
Pacher M; Seewald MJ; Mikula M; Oehler S; Mogg M; Vinatzer U; Eger A; Schweifer N; Varecka R; Sommergruber W; Mikulits W; Schreiber M
Carcinogenesis; 2007 Jan; 28(1):49-59. PubMed ID: 16774935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
